Monthly Archives: February 2010


Patients with rare cancer get second chance to fight back

When Morty Wagman underwent surgery to remove a gastrointestinal stromal tumour (GIST) in 2008 with his wife Judi by his side, he was faced with a concerning 55 percent chance that his cancer would return. Then, his oncologist told him about Gleevec (imatinib), a treatment that could greatly reduce the risk of his cancer returning, and Wagman felt empowered and hopeful. Today, he and his wife applaud Health Canada for approving Gleevec for patients with this potentially life-threatening condition, at an earlier stage in the disease.

By |2013-08-19T10:52:06-04:00February 1st, 2010|News|

Insomnia is common, likely under-diagnosed among people with cancer undergoing chemo

Researchers have found that 43 percent of patients undergoing chemotherapy for cancer in a clinical trial met the clinical criteria for insomnia syndrome and an additional 37 percent had insomnia symptoms, suggesting that the majority of patients (80 percent) experience sleep difficulties. This rate is approximately two to three times higher than that seen in the general population. Insomnia syndrome is defined as difficulty sleeping three or more times per week for at least a month, and can cause significant distress or impairment in daytime functioning. The study was published in the Journal of Clinical Oncology.

By |2019-11-25T14:53:05-05:00February 1st, 2010|Coping with GIST, Side Effects|

Synta opens phase II trial STA-9090 in GIST

STA-9090 is a synthetic, small molecule HSP90 inhibitor. It has a unique chemical structure different from earlier HSP-90 inhibitors that, like IPI-504, are first generation drugs based on a family of antibiotics called ansamycins. As a result, STA-9090 is likely to have a different toxicity profile.

By |2019-12-26T15:39:43-05:00February 1st, 2010|Clinical Trials, News|

Tasigna shows greater efficacy over Gleevec for CML: Will GIST be next?

For the past eight years, Gleevec has been the first-line treatment for adult patients with c-Kit (CD117)-positive, unresectable and/or metastatic malignant GISTs. But for some patients, Gleevec is not the answer to their prayers. A small percentage, five to 15 percent, do not benefit from Gleevec from the outset. Others develop a resistance to the drug or cannot tolerate the side effects.

By |2019-12-26T15:37:41-05:00February 1st, 2010|Gleevec, News|
Go to Top